Diadema Partners LP Takes $2.29 Million Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Diadema Partners LP purchased a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,620 shares of the company's stock, valued at approximately $2,293,000. Apogee Therapeutics makes up 1.0% of Diadema Partners LP's holdings, making the stock its 21st biggest holding. Diadema Partners LP owned about 0.11% of Apogee Therapeutics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Barclays PLC raised its position in shares of Apogee Therapeutics by 369.2% during the 3rd quarter. Barclays PLC now owns 365,046 shares of the company's stock valued at $21,443,000 after buying an additional 287,243 shares in the last quarter. Geode Capital Management LLC raised its holdings in Apogee Therapeutics by 11.2% during the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company's stock valued at $48,401,000 after buying an additional 82,978 shares during the period. JPMorgan Chase & Co. lifted its position in Apogee Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company's stock worth $1,736,000 after buying an additional 1,212 shares during the last quarter. SG Americas Securities LLC boosted its stake in Apogee Therapeutics by 22.2% during the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company's stock worth $448,000 after buying an additional 1,796 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Apogee Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company's stock worth $432,000 after buying an additional 892 shares during the period. Institutional investors own 79.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Citigroup assumed coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 target price for the company. Wedbush restated an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $92.17.

Apogee Therapeutics Stock Down 0.5 %

APGE traded down $0.20 on Friday, reaching $36.85. 578,730 shares of the company traded hands, compared to its average volume of 512,343. The company has a market cap of $1.66 billion, a P/E ratio of -15.23 and a beta of 1.72. The firm has a fifty day simple moving average of $35.15 and a two-hundred day simple moving average of $42.81. Apogee Therapeutics, Inc. has a one year low of $26.20 and a one year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). On average, equities analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 1,590 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20. Following the completion of the transaction, the insider now owns 251,033 shares in the company, valued at $7,651,485.84. The trade was a 0.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael Thomas Henderson sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total transaction of $608,700.00. Following the completion of the sale, the chief executive officer now owns 1,302,987 shares of the company's stock, valued at approximately $52,875,212.46. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,970 shares of company stock worth $1,241,701 in the last three months. 36.10% of the stock is owned by insiders.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.